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BRCA1 and BRCA2, two genetic models of breast cancer
Breast cancer is one of the most frequent malignancies aecting women. The cumulative lifetime risk of a female for the development of this disease is about 10% (Claus et al., 1991) . For this reason, breast cancer has been the subject of intense study; however, the mechanism underlying breast cancer formation is still largely unknown. In the last decade of the 20th century, two breast cancer susceptibility genes, BRCA1 and BRCA2, which together are responsible for most of the hereditary breast cancer cases, were identi®ed (Hall et al., 1990; Miki et al., 1994; Wooster et al., 1994 Wooster et al., , 1995 . Mutations in BRCA1 account for almost all of the hereditary breast and ovarian cancer cases and up to 40 ± 50% of families with hereditary breast cancer only (Easton et al., 1993) . Mutations in BRCA2 are linked to the other half of inherited breast cancer families and also to male breast cancer (Wooster et al., 1994 (Wooster et al., , 1995 . The identi®cation of familial breast cancer susceptibility genes has provided two human genetic models for studies of breast cancer.
To understand how the loss of BRCA1 or BRCA2 function leads to breast cancer formation, mouse genetic models for BRCA1 or BRCA2 mutations have been established. This work has revealed that Brca1 homozygous deletions are lethal at early embryonic days (E)5.5 ± 13.5 (Gowen et al., 1996; Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997) . Three independent groups generated distinct mutations within Brca1, yet nonetheless observed similar embryonic phenotypes, including defects in both gastrulation and cellular proliferation, and death at E6.5 (Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997) . A fourth group that generated a distinct Brca1 mutation observed embryos that survived until E13.5 and exhibited defects in neural development, including anencephaly and spina bi®da to varying degrees (Gowen et al., 1996) . A ®fth group generated a mouse model with a targeted deletion of Brca1 exon 11. The resultant mutant embryos expressed an exon 11-deletion variant of Brca1 and died at E12 ± 18.5 (Xu et al., 1999b) . Collectively, these ®ndings imply a role for the Brca1 gene product in growth and/or dierentiation during mouse embryogenesis.
Similarly, three separate groups have demonstrated that mice homozygous for a Brca2 truncation mutation at the 5' end of exon 11 die at E8.5 ± 9.5 of gestation (Ludwig et al., 1997; Sharan et al., 1997; Suzuki et al., 1997) . Prior to growth arrest, the mutant embryos appear to have been dierentiating and to be forming mesoderm, suggesting that the in¯uence of Brca2 during mouse embryogenesis is manifest more on proliferation than dierentiation. Mice homozygous for a Brca2 truncation mutation at the 3' end of exon 11 also exhibit progressive proliferative impairment and die prenatally or perinatally; those animals that do survive to adulthood, however, develop lethal thymic lymphomas (Connor et al., 1997; Friedman et al., 1998) .
Although these mouse models have revealed a fundamental role for BRCA1 and BRCA2 in embryogenesis, mice carrying heterozygous Brca1 and Brca2 mutations develop normally and are no more susceptible to tumors than their normal littermates. The lack of tumor formation in mice heterozygous for Brca1 or Brca2 has rendered it dicult to study the pathogenesis of breast cancer. However, the recent establishment of a conditional knockout animal model has provided a useful system with which to study early events in breast tumor formation (Deng and Scott, 2000) .
By exploiting the mammary epithelium-speci®c expression of a MMTV-Cre or WAP-Cre transgene to induce a Cre-LoxP mediated deletion of brca1 exon 11 in mammary epithelium, it was reported that ®ve out of 23 MMTV-Cre or WAP-Cre female mice developed diverse mammary tumors by 10 ± 13 months of age (Xu et al., 1999a) . Most of the tumors analysed were found to carry p53 mutations, an observation consistent with previous reports from studies of human BRCA1 familial breast tumors (Crook et al., 1997; Eisinger et al., 1997) . These observations imply a link between p53 mutation and Brca1-associated mammary tumor development, a notion further supported by a documented acceleration in both the frequency and age of onset of breast tumor formation accompanying inactivation of one germline copy of p53 in these conditional Brca1 knockout mice (Xu et al., 1999a) . Collectively, these observations support a role for BRCA1 as a breast cancer suppressor gene.
Evidence to support a role for BRCA2 as a tumor suppressor includes the observation of tumorigenesis in mice homozygous for a Brca2 truncation mutation at the 3' end of exon 11 (Connor et al., 1997; . Inactivating mutations in mitotic checkpoint genes such as Bub1, Mad3L and p53, whose products are pressed into action as a consequence of chromosomal damage, are believed to relieve growth arrest caused by BRCA2 de®ciency and precipitate neoplastic transformation . Nevertheless, a suitable breast cancer model for studying the role of BRCA2 in breast cancer development remains to be established.
Both BRCA1 and BRCA2-de®cient cells are characterized by cumulative chromosome abnormalities, including chromosomal breaks, aberrant mitotic exchanges and aneuploidy Xu et al., 1999b) . Chromosomal instability has been proposed as the pathogenic basis for mammary tumor formation caused by BRCA1 and BRCA2 de®ciency. Paradoxically, chromosomal instability is invariably accompanied by growth arrest or increased cell death, and the early embryonic lethality associated with BRCA1 or BRCA2 de®ciency has been attributed to these cellular responses. How then might BRCA1 or BRCA2 mutation lead ultimately to uncontrolled cell growth and tumor formation? One answer to this question may lie in the observation that tumors found in Brca1 and Brca2-de®cient mice harbor additional inactivating mutations in p53 and mitotic checkpoint genes Xu et al., 1999b) . Thus, mutational inactivation of p53, which governs the G1/S cell cycle checkpoint, may circumvent the growth arrest that is normally induced upon DNA damage, and also inhibit p53-mediated apoptosis, thereby permitting the survival of cells with severe chromosomal damage. Consistently, the embryonic lethality associated with brca1-null mutations can be partially rescued by targeted deletion of p53 or p21 . On the other hand, inactivation of mitotic checkpoint genes could bypass mitotic arrest and permit aberrant chromosomes to segregate into progeny cells. Hence, the cumulative evidence suggests that the genetic instability arising in Brca1-or Brca2-de®cient cells plays a pivotal role in tumorigenesis, leading ®rst to compensatory gene mutations that override chromosomal damage-induced cell cycle arrest and apoptosis and, subsequently, to the accrual of functionally inactivating mutations at genetic loci involved in breast tumorigenesis.
Analysis of BRCA1-and BRCA2-de®cient cells
The establishment of culture cell lines de®cient in either BRCA1 or BRCA2 has facilitated studies designed to de®ne and characterize their corresponding biological activities. Cell lines established from clinical tumor specimens include the BRCA1-de®cient human breast adenocarcinoma HCC1937 cell line and the BRCA2-de®cient human pancreatic carcinoma CAPAN-1 cell line. Brca1 and Brca2-de®cient mouse embryos derived from gene targeting events have also served as an invaluable source of Brca1 and Brca2-de®cient stem (ES) and ®broblast (MEF) cell lines for fundamental research purposes.
BRCA1-de®cient HCC1937 cells, BRCA1-null ES cells, and Brca1-exon 11 deletion MEF cells are all characterized by radiation hypersensitivity. Increased sensitivity to the radiomimetic agent methyl methanesulfonate (MMS) and ionizing radiation (IR), but not to ultraviolet (UV) radiation, has also been observed in BRCA1-de®cient cells (Gowen et al., 1998; Scully et al., 1999; Xu et al., 1999b; Zhong et al., 1999) . Reintroduction of a wild-type BRCA1 allele, but not clinically validated BRCA1 missense mutant alleles, can complement the MMS and IR sensitivity of BRCA1-de®cient cells, suggesting that the cellular response to DNA damage is compromised in breast cancer patients carrying BRCA1 mutations (Scully et al., 1999; Zhong et al., 1999) . BRCA1-null ES cells are defective in the repair of both oxidative DNA damage by transcription-coupled processes (Gowen et al., 1998) and chromosomal double-strand breaks by homologous recombination (Moynahan et al., 1999) . Defective control of the DNA-damage induced G2/M checkpoint has also been observed in BRCA1-exon 11 deletion MEFs, thereby implicating BRCA1 in cell cycle checkpoint control (Xu et al., 1999b) . Improper centrosome duplication is another prominent characteristic of these cells leading to multipolar spindle formation and consequent unequal chromosomal segregation and micronuclei formation (Xu et al., 1999b) . Although a function in centrosome duplication is consistent with the reported localization of the BRCA1 protein to centrosomes (Hsu and White, 1998) , multiple centrosomes could be formed as a consequence of accumulated DNA damage in Brca1-de®cient cells, as it has been shown that DNA damage can trigger improper centrosome activity followed by micronuclei formation (Sibon et al., 2000; Su and Vidwans, 2000) . Nonetheless, improper centrosome duplication is likely to exacerbate pre-existing genomic instability that has arisen from defects in the surveillance and repair of damaged DNA. Taken together, the phenotypic characteristics of BRCA1-de®cient cells suggest that BRCA1 occupies a central role in the cellular DNA damage response by virtue of its dual participation in DNA damage repair and cell cycle checkpoint control.
Hypersensitivity to genotoxic agents including UV, MMS, and IR has been reported to be characteristic of BRCA2-de®cient cells, including tumor-derived CA-PAN-1 cells, Brca2-de®cient mouse blastocysts and MEFs (Chen et al., 1998b; Connor et al., 1997; Sharan et al., 1997) . It has also been observed that the level of unrepaired DNA double-strand breaks is abnormally elevated in Brca2-de®cient MEFs following IR-treatment, suggesting that Brca2 is also required for ecient DNA repair (Connor et al., 1997) .
Analysis of functional domains recognized in BRCA1 and BRCA2
Genetic studies have revealed BRCA1 and BRCA2 to be essential for cell growth and survival, critical for an appropriate cellular response to DNA damage, and important etiological factors in the development of cancer. In parallel, functional analyses of their corresponding gene products have been carried out in order to understand how BRCA1 and BRCA2 execute these functions.
The BRCA1 gene encodes a nuclear phosphoprotein of 1863 amino acids (Chen et al., 1996b,c; Miki et al., 1994) characterized by the presence of two outstanding structural motifs at each of its¯anking termini ( Figure  1a ). At its amino terminus, BRCA1 harbors a structurally conserved RING ®nger domain (amino acids 24 ± 64). The RING ®ngers is a zinc-binding motif characterized by a set of spatially conserved cysteine and histidine residues that follow the linear order C3HC4 within the primary amino acid sequence. The RING ®nger motif of BRCA1 does not appear to represent a DNA-binding domain, but is apparently involved in protein ± protein interactions (Saurin et al., 1996) . Two proteins, BARD1 and BAP1, have been identi®ed based on their ability to bind to the BRCA1 RING ®nger domain (Jensen et al., 1998; Wu et al., 1996) .
The C-terminal region of BRCA1 was ®rst characterized as a transactivation domain (Chapman and Verma, 1996; Chen et al., 1996a; Monteiro et al., 1996) . This region also contains two tandem BRCT (BRCA1 C-terminal) domains (amino acids 1640 ± 1863). An autonomous folding unit de®ned by conserved clusters of hydrophobic amino acids, the BRCT domain is found in a diverse group of proteins implicated in DNA repair and cell cycle check-point control (Bork et al., 1997; Callebaut and Mornon, 1997; Koonin et al., 1996) . While no speci®c cellular function has been ascribed to the BRCT domain, this motif is likely to represent a protein interaction surface (Saka et al., 1997) . The BRCT domain in BRCA1 mediates its interaction with proteins such as RNA helicase A, CtIP, and histone deacetylases (Table 1) Li et al., 1999b; Wong et al., 1998; Yarden and Brody, 1999; Yu et al., 1998) .
Yet another region in BRCA1, which is encoded by the 5'-region of exon 11 appears to have an emerging role as a functionally relevant protein ± protein interaction surface . Although the structure of this region has not yet been de®ned, it nonetheless mediates the interaction of BRCA1 with many proteins including BRAP2, p53, c-Myc, and RAD50 (Table 1) (Li et al., 1998; Wang et al., 1998; Zhang et al., 1998; Zhong et al., 1999) . This region also includes two putative nuclear localization signals, which have been shown to interact with importin a (Chen et al., 1996a) .
The BRCA2 gene encodes a nuclear phosphoprotein of 3418 amino acids (Figure 1b) Wooster et al., 1995) . Sequence analysis has revealed that its exon 3-encoded region shares some sequence similarity with the transactivation domain present in cJun, and functional analysis has con®rmed the presence of an inherent transactivation function within this region (Milner et al., 1997) . A prominent architectural feature resident within the BRCA2 primary amino acid sequence comprises eight tandem copies of a repetitive (Chen et al., 1998b; Wong et al., 1997) . A third notable region within the BRCA2 primary amino acid sequence, spanning residues 2472 to 2957, represents a region of higher sequence conservation between human and mouse BRCA2 than the coding sequence as a whole. An evolutionarily conserved protein, DSS1 (deleted in split hand/split foot), has been found to interact with BRCA2 in this region, although the signi®cance of this interaction is not clear (Marston et al., 1999) . Protein interaction studies thus provide independent support for a potential role of BRCA1 and BRCA2 in DNA damage repair by revealing their interactions with RAD50 and RAD51, respectively. Correspondingly, a role for BRCA1 and BRCA2 in transcription regulation is supported by both the identi®cation in each of an autonomous transactivation function, and protein interaction pro®ling that reveals the interaction of each with a variety of transcriptional activators and repressor proteins.
Molecular basis of BRCA1 and BRCA2 function
BRCA1 in transcription regulation BRCA1-mediated transcriptional activation A role for BRCA1 in transcriptional regulation was initially indicated by the identi®cation of an acidic domain near the carboxyl-terminus of BRCA1 with an inherent transactivation function that is sensitive to cancerpredisposing mutations (Chapman and Verma, 1996; Chen et al., 1996a; Monteiro et al., 1996) . When fused to a heterologous DNA-binding domain, a carboxyterminal fragment of BRCA1 (amino acids 1560 ± 1863) was observed to exhibit strong transcriptional activity in mammalian cells, and this activity was completely abolished by familial breast cancer-derived BRCA1 mutations (Chapman and Verma, 1996; Monteiro et al., 1996) . This region, as well as a second, partially overlapping region (amino acids 1142 ± 1643) was also found to confer similar transactivation activity in yeast cells (Chen et al., 1996a ). An inherent transactivation function within this region of BRCA1 is further supported by a recent study showing that this region, when expressed recombinantly with a heterologous DNA binding domain, can activate transcription in vitro in a highly puri®ed reconstituted transcription system (Haile and Parvin, 1999) . The presence of an autonomous transactivation function within BRCA1, coupled with the absence of demonstrable sequencespeci®c DNA-binding activity, had led to the hypothesis that BRCA1 functions as a co-activator of transcription.
Biological implications of BRCA1-mediated transcriptional activation Recent studies utilizing gene expression pro®ling methodologies have revealed that ectopic overexpression of BRCA1 can induce a diverse array of genes implicated in cell growth control, cell cycle regulation, and DNA replication and repair. Included among these are the genes encoding p21, GADD45, EGR1, PCNA, CDC34, Ku70, K80, and GADD153 (Harkin et al., 1999; MacLachlan et al., 2000) . As BRCA1 protein levels increase between mid-S and G2 phases of the cell cycle (Chen et al., 1996c) , it is possible that BRCA1 overexpression strategies may simulate the status of BRCA1 during these physiological periods and thereby provide at least a limited window onto the spectrum of target genes under its transcriptional control.
While the transactivation function of BRCA1 is likely to contribute to its role in the regulation of gene expression, it is not presently clear how BRCA1 mediates gene-speci®c transcription control. Since BRCA1 does not appear to bind speci®c DNA sequences, it seems likely that it must interact with sequence-speci®c DNA-binding transcription factors in order to target unique genetic loci. As a sequencespeci®c DNA-binding transcription factor, the universal tumor suppressor p53 may represent an important link between BRCA1 and gene-speci®c transcription control. p53 lies at the heart of a cell-signaling pathway that is triggered by genotoxic stresses, including DNA damage. Stress-induced p53-initiated cell cycle arrest and/or apoptosis ensures the timely repair or elimination of potentially deleterious genetic lesions. Signi®-cantly, p53 and BRCA1 appear to regulate transcription from an overlapping set of DNA damage-inducible target genes, including p21 and GADD45. This observation initially implied a functional interaction between these two important tumor suppressors, a prediction that has since been borne out experimentally. BRCA1 and p53 have been demonstrated to interact physically and synergize functionally to activate transcription through p53 binding sites located in both the p21 promoter and GADD45 intron 3 sequences (Chai et al., 1999; Ouchi et al., 1998; Zhang et al., 1998) . The ability of BRCA1 to potentiate p53-dependent transcription absent DNA binding has led to the hypothesis that BRCA1 functions as a p53-speci®c co-activator, possibly linking the biochemical activities of these two proteins to a common pathway of tumor suppression. Nevertheless, BRCA1 can also regulate promoter activity and induce gene expression in a p53-independent manner (Somasundaram et al., 1997; Harkin et al., 1999) . Therefore, additional unidenti®ed DNA-binding transcription factors must function to recruit BRCA1 to speci®c target genes.
Mechanistic basis for BRCA1-mediated transcriptional activation The initiation of RNA polymerase II transcription represents a principal step targeted for regulation within the cell. Gene-speci®c activators function to stimulate the rate of transcription initiation largely through the recruitment of either chromatin remodeling activities and/or the general transcription machinery in order to override nucleosome-mediated promoter repression and assemble transcription-competent pre-initiation complexes, respectively. While the underlying mechanism by which BRCA1 mediates gene-speci®c transcriptional activation remains to be established, current experimental observation is consistent with a role for BRCA1 in both of these recruitment steps.
Lessons learned from BRCA1 and BRCA2 L Zheng et al First, BRCA1 could play a role in the recruitment of chromatin remodeling activities. BRCA1 has been demonstrated to interact directly or indirectly with chromatin modifying activities including p300 (Pao et al., 2000) , hBRG1 (Neish et al., 1998) , and BRCA2 (Chen et al., 1998a) which itself is associated with histone acetyltransferase activity (Fuks et al., 1998; Siddique et al., 1998) . In addition, it has recently been demonstrated that the BRCA1 carboxyl-terminal transactivation domain, when targeted to chromatin via a heterologous DNA-binding domain, can alter local chromatin structure . Signi®cantly, the same cancer-predisposing mutations that abolish its transcriptional activation function also abrogate the ability of this domain to eect chromatin remodeling , perhaps implicating direct recruitment of chromatin modifying activities as a mechanistic basis for the disruptive in¯uence of this region.
A second step at which BRCA1 is likely to function in transcriptional activation involves RNA polymerase II holoenzyme recruitment. This possibility is supported by several studies that link BRCA1 to the RNA polymerase II holoenzyme through demonstrated interactions with constituent holoenzyme components, including RNA helicase A (RHA) Scully et al., 1997a) , CBP/p300 (Pao et al., 2000) , and RNA polymerase II itself (Schlegel et al., 2000) . The ability of BRCA1 to bind to RNA helicase A has been shown to be essential for the transactivation activity of BRCA1, suggesting a direct functional link between BRCA1 and the holoenzyme. CBP/p300 has been found to interact with BRCA1 in vitro and in vivo, and to stimulate BRCA1-directed transcription activation (Pao et al., 2000) . Recently, BRCA1 has been shown to bind speci®cally to RNA polymerase II subunits hRPB2 and hRPB10a in vitro (Schlegel et al., 2000) . Moreover, excess recombinant hRPB2 and hRBP10a, but not other polymerase subunits, were found to be capable of blocking activated transcription in vitro by the BRCA1 carboxyl-terminal transactivation domain, suggesting that direct interactions between BRCA1 and core RNA polymerase II could potentially mediate BRCA1-dependent transcriptional activation. Taken together, these observations implicate multiple components within the RNA polymerase II holoenzyme for potential contact by BRCA1. Accordingly, a plausible model to account for transcriptional activation by BRCA1 is that gene-speci®c activators, by virtue of their interaction with BRCA1, recruit the RNA polymerase II holoenzyme onto target promoters in order to eect an increase in the transcription rate of genes under their control.
Yet another mechanism by which BRCA1 could potentially function to stimulate transcription invokes targeting of post-initiation processes, including transcription elongation. The observation that Brca1-de®-cient ES cells are defective in transcription-coupled repair of oxidative DNA damage (Gowen et al., 1998) suggests a link between BRCA1 and RNA polymerase II actively engaged in transcript synthesis. Future studies will be required to more precisely de®ne the potential regulatory role that BRCA1 plays in steps subsequent to RNA polymerase II transcription initiation.
BRCA1-mediated transcriptional repression
Somewhat paradoxically, the carboxyl-terminus of BRCA1 that both binds transcriptional coactivators and encodes a potent transactivation domain also mediates the interaction of BRCA1 with transcriptional corepressors including the CtIP/CtBP complex and histone deactylases (HDACs) Yarden and Brody, 1999) . Interestingly, familial breast cancer-derived mutations that compromise its transactivation activity also abolish the binding of BRCA1 to CtIP and HDACs. These observations have prompted the speculation that BRCA1 may function analogously to nuclear receptors, which function both as activators and repressors depending on their associated cofactors (Pao et al., 2000) . These observations also suggest the intriguing possibility that apparent BRCA1-mediated transcriptional induction may derive, at least in part, from derepression by BRCA1-mediated corepressor titration.
BRCA1 has been shown to repress c-Myc-mediated transcriptional activation (Wang et al., 1998) and also to inhibit the transactivation activity of estrogen receptor (Fan et al., 1999) . The negative eect of BRCA1 on cMyc-mediated transactivation could derive from transrepression involving inhibition of either Myc-Max heterodimer formation or DNA binding by Myc-Max heterodimers (Wang et al., 1998) . BRCA1-mediated inhibition of estrogen receptor-mediated transactivation could re¯ect either direct repressive eects at the promoter or, alternatively, indirect repression through disruption of signaling events that activate the estrogen receptor (Fan et al., 1999) .
The association of BRCA1 with CtIP/CtBP or HDACs suggests a more direct role for BRCA1 in active repression and, thus provides an alternative explanation for the negative eect of BRCA1 on transcription. A direct role for BRCA1 in transcriptional repression is supported by a recent study showing that BRCA1 can mediate sequence-speci®c transcriptional repression through its selective recruitment by a novel DNA-binding transcription factor, ZBRK1 (zinc-®nger and BRCA1-interacting protein with a KRAB domain). In this study, BRCA1 is shown to mediate ZBRK1-directed repression through a ZBRK1 binding site identi®ed in intron 3 of the GADD45 gene, thus providing a potential mechanistic link between the activities of BRCA1 in gene-speci®c transcription control, the cellular DNA damage response, and the maintenance of genome integrity .
Biological implications of BRCA1-mediated transcriptional repression BRCA1 has been reported to repress c-Myc-mediated transcriptional activation from synthetic promoters carrying c-Myc response elements as well as from the natural c-Myc-responsive CDC25A promoter (Wang et al., 1998) . Furthermore, this BRCA1-mediated transcriptional repression can be correlated with its inhibition of Myc-mediated cellular transformation, thus providing one potential mechanism for BRCA1-mediated tumor suppression (Wang et al., 1998) .
BRCA1-mediated transcriptional repression has also been implicated in silencing the DNA-damage inducible p21 and GADD45 genes in their uninduced states. Support for this model has been provided by a recent study showing that BRCA1 may be physically tethered and functionally linked to a speci®c regulatory locus within GADD45 through the sequence-speci®c DNAbinding transcription repressor ZBRK1 . This study also reveals that relief of ZBRK1-directed GADD45 repression may be achieved by ectopic overexpression of BRCA1, most likely by altering the balance of repression components speci®-cally recruited to DNA-bound ZBRK1. This unexpected observation raises the possibility that activation of GADD45 transcription in the natural setting may re¯ect the concerted eects of both derepression and true activation.
While derepression by BRCA1 overexpression may accurately re¯ect some aspect of its function in vivo, more physiologically relevant mechanisms for derepression are likely to involve alterations in the phosphorylation and/or protein interaction status of BRCA1. In this regard, DNA damage-induced dissociation of a CtIP-CtBP corepressor complex from BRCA1 could relieve ZBRK1 repression of GADD45 transcription, thereby leading to GADD45 induction in response to DNA damage-induced signaling. A similar mechanism may also underlie p21 induction.
BRCA1-mediated control of p21 and GADD45 gene transcription may contribute to its role in cell cycle checkpoint control, since p21 and GADD45 have been implicated in DNA-damage induced G1/S and G2/M checkpoint control, respectively (el-Deiry et al., 1993; Deng et al., 1995; Brugarolas et al., 1995; Wang et al., 1999) . Consistent with this possibility, GADD45 induction in response to MMS or UV has been shown to be dependent on BRCA1 (Harkin et al., 1999) . Thus, mutational inactivation of BRCA1 or its associated factors could lead to alterations in the normal induction pro®le of GADD45 and a resultant failure of cells to achieve an appropriate G2/M arrest. While GADD45 induction triggered by IR has been shown to require ATM and p53 (Kastan et al., 1992) , the involvement of BRCA1 is not clear. However, several recent studies have implicated BRCA1 in the IR pathway possibly leading to GADD45 induction. First, it has been shown that BRCA1 can potentiate transcription from p53-response elements within the GADD45 gene in a p53-dependent manner (Harkin et al., 1999) . Second, BRCA1 has been identi®ed as a downstream target of ATM in a DNA damage induced signaling pathway following IR (Cortez et al., 1999) . Nonetheless, direct supporting evidence of a regulatory role for BRCA1 in GADD45-mediated G2/M checkpoint control is currently lacking.
Gene expression pro®ling studies have established a number of genes to be downregulated in response to BRCA1 overexpression, thus identifying potential targets of BRCA1-mediated transcriptional repression. Included among these are Cyclin B1 and PIN1 (MacLachlan et al., 2000) . Cyclin B1, the activating subunit of cdc2 kinase (reviewed by Nurse, 1994) , and PIN1, a peptidyl-prolyl isomerase (Lu et al., 1996) , are both involved in mediating cellular progression into and through mitosis. BRCA1-mediated repression of these genes could be expected to arrest cells at the G2/M cell cycle transition phase, thereby providing an additional potential mechanism through which BRCA1 could achieve G2/M cell cycle checkpoint control (MacLachlan et al., 2000) . Precisely how DNA damage-induced signaling might activate BRCA1 to eect transcriptional repression of Cyclin B1 or PIN1, however, remains to be elucidated. Alternatively, it is possible that BRCA1 could regulate G2/M phase traversal during the normal cell cycle through regulation of Cyclin B1 and PIN1.
A recent study documenting BRCA1-mediated repression of estrogen receptor transcriptional activity invokes a potential role of BRCA1 in the estrogensignaling pathway (Fan et al., 1999) . This pathway controls multiple aspects of breast and ovarian cell growth, dierentiation and homeostasis. Furthermore, estrogen itself is a distinct etiological factor in breast and ovarian cancer. By aecting hormone response pathways, BRCA1 may regulate growth or a dierentiation in a cell-type speci®c manner.
Mechanistic basis for BRCA1-mediated transcriptional repression Insight into the potential mechanism(s) by which BRCA1 mediates the repression of speci®c target genes has come from protein interaction studies that link BRCA1 to established transcriptional repression activities, including the CtIP/CtBP corepressor complex and histone deacetylases. Human CtBP was initially identi®ed as an adenovirus E1A C-terminal interacting protein capable of attenuating E1A-mediated transcriptional activation and tumorigenesis (Schaeper et al., 1995) . A corepressor function for CtBP was subsequently revealed through the interaction of Drosophila CtBP with three transcriptional repressors, Knirps, Snail, and Hairy (Nibu et al., 1998; Poortinga et al., 1998) . Mammalian homologs of CtBP have also been found to serve as corepressors for a variety of DNA-binding transcriptional repressors (Furusawa et al., 1999; Postigo and Dean, 1999; Turner and Crossley, 1998) . Each of these CtBPinteracting transcriptional repressors harbors a conserved amino acid sequence motif, PLDLS, that was originally identi®ed in E1A and that speci®es the association of each with CtBP (Sollerbrandt et al., 1996) .
The same sequence motif present in CtBP-interacting transcriptional repressors also speci®es the interaction of CtBP with CtIP, a protein initially identi®ed by virtue of this interaction (Schaeper et al., 1998) . Remarkably, an interaction between CtIP and BRCA1 was simultaneously identi®ed by several groups Wong et al., 1998; Yu et al., 1998) , and CtIP was found to link the corepressor CtBP to BRCA1 . Interestingly, a second tumor suppressor, the retinoblastoma (Rb) protein, as well as one of its associated family members, p130, also interact with CtIP. This observation led to the hypothesis that the transcriptional repression activity of Rb and p130 might be mediated by recruitment of CtBP through CtIP (Meloni et al., 1999) . Its speci®c interaction with two distinct tumor suppressor proteins, BRCA1 and Rb, imply a fundamental role for CtIP in tumor suppression.
Another distinct corepressor complex with which BRCA1 interacts is the histone deacetylase complex (Yarden and Brody, 1999) . Initially identi®ed based on its copuri®cation with mSin3, histone deacetylase complex components include two proteins initially identi®ed as Rb-associated proteins, RbAp48 and RbAp46, two histone deacetylases, HDAC1 and HDAC2, two additional polypeptides, SAP18 and SAP30, and additional unidenti®ed factors (for review, see Pazin and Kadonaga, 1997; and references therein). Sin3 and nuclear receptor corepressors, N-CoR/ SMRT, are also components of the histone deacetylase complex and appear to function in establishing the protein ± protein links between DNA-bound repressors and the histone deacetylases. The association of NCoR/SMRT with HDAC1/2 is mediated by mSin3 (Pazin and Kadonaga, 1997). Besides HDAC1 and HDAC2, which comprise class I histone deacetylases, other HDAC family proteins have been identi®ed, including class I HDAC3, and class II HDAC4, HDAC5, HDAC6 and HDAC7. Recently, N-CoR/ SMRT have been found to interact directly with class II histone deacetylases, suggesting that these corepressors can recruit histone deacetylases in a mSIN3-independent manner (for review, see Glass and Rosenfeld, 2000; and references therein) . BRAC1 has been shown to associate with at least four components of histone, deacetylase complexes, including HDAC1/2 and RbAp46/RbAp48 (Yarden and Brody, 1999) . This observation suggests that BRCA1-mediated transcriptional repression may derive, at least in part, from active recruitment of HDACs.
While the precise mechanism by which BRCA1 mediates gene-speci®c transcriptional repression remains to be established, current experimental observation is consistent with several alternative possibilities (Figure 2) . First, BRCA1 corepression could involve targeted chromatin remodeling. For example, BRCA1 could, by virtue of its direct recruitment of HDAC complexes, alter the chromatin structure of its target genes into a repression-favored status. Alternatively, BRCA1 could aect remodeling via its interaction with the CtIP-CtBP corepressor complex. CtBP itself interacts directly with HPC2, the human homolog of Drosophila polycomb (Sewalt et al., 1999) . HPC2 is part of a polycomb group (PcG) protein complex that functions in repression of homeotic gene expression during vertebrate development. The PcG proteins have been proposed to confer heritable and stable transcriptional repression by packaging target genes into heterochromatin-like con®gurations or, alternatively, by relocalizing target genes into heterchromatic compartments (Sewalt et al., 1999) . Recently, a histone deacetylase-independent CtBP repression mechanism has been described (Koipally and Georgopoulos, 2000) , suggesting the possibility of multiple independent paths to achieve repression through a putative BRCA1-CtIPCtBP complex. Alternatively, the association of BRCA1 with the RNA polymerase II holoenzyme may evince a distinct mechanism for corepression by which BRCA1 directly targets either the general transcription machinery or interacting coactivators.
BRCA1 in DNA repair
BRCA1 appears to participate in the cellular DNA damage response at multiple stages. In normal cells, responses to DNA damage include sensing damaged DNA, transducing DNA damage signals, relocating repair machinery to damage sites, completing a repair process, and coordinating cell cycle progression with the DNA repair process. Accumulating evidence suggests that BRCA1 functions not only in association with the DNA repair machinery, but also in DNAdamage induced cell cycle checkpoint control. Additionally, BRCA1 may regulate the expression of genes involved in DNA damage repair and, signi®cantly, it directly participates in the repair process itself. Finally, phosphorylation of BRCA1 upon DNA damage implies a role for BRCA1 in DNA damage-induced signal relay.
The interaction between BRCA1 and the DNA repair machinery BRCA1 has been shown to associate directly with the RAD50/MRE11/NBS1 complex . Its equivalent complex in yeast, the Rad50/Mre11/Xrs2 complex, functions in both non-homologous end-joining (NHEJ) and homologous recombinational repair of DNA double-strand breaks. Yeast strains de®cient in MRE11, RAD50, or XRS2 exhibit a 50-to 100-fold decrease in NHEJ in the absence of the RAD52-dependent homologous recombination pathway (Ivanov et al., 1992; Johzuka and Ogawa, 1995) . A role in facilitating homologous recombination in mitotic cells has also been established for this complex (Bressan et al., 1999) . Meanwhile, Mre11, Rad50, and Xrs2 are necessary for introduction of chromosomal double-strand breaks (DSB) that lead to homologous recombination during meiosis in yeast (Ivanov et al., 1992; Johzuka and Ogawa, 1995; Ohta et al., 1998) . In addition, they are involved in other cellular processes including chromatin con®guration and telomere maintenance (Boulton and Jackson, 1998; Chamankhah et al., 2000; Chamankhah and Xiao, 1999; Gerecke and Zolan, 2000; Nugent et al., 1998; Ohta et al., 1998) . It has been proposed that RAD50/ MRE11/XRS2 is responsible for end-processing of double-strand breaks (Tsubouchi and Ogawa, 1998) . In support for this idea, recombinant MRE11 proteins and puri®ed human RAD50/MRE11/NBS1 complexes exhibit exonuclease and endonuclease activities (Paull and Gellert, 1998; Trujillo et al., 1998) . The mechanistic role of RAD50 in this complex is not clear, although it has been shown that the exonuclease activity of MRE11 in complex with RAD50 is moderately increased (Paull and Gellert, 1998) . Based on the structural similarity between RAD50 and SMC family proteins, it has been proposed that RAD50 may be a chromatin-associated protein and participate in Figure 2 Sequence-speci®c transcription repression mediated by BRCA1. ZBRK1 represents the sequence-speci®c transcription repressor that recruits BRCA1 to speci®c DNA-binding sites in its target genes. BRCA1 mediates transcription repression through three potential mechanisms. First, BRCA1 may recruit CtIP/CtBP to mediate reorganization of higher order chromatin structure. Second, BRCA1 may recruit the histone deacetylase complex to mediate local gene silencing. Third, BRCA1 may repress transcription by regulating the basal transcription machinery chromatin structural recon®guration (Alani et al., 1989) . NBS1, the human equivalent of yeast Xrs2, was identi®ed based on its copuri®cation with RAD50 and MRE11, and simultaneously as the product of the gene mutated in Nijmegen break syndrome (Carney et al., 1998; Varon et al., 1998b) . The RAD50/MRE11/ NBS1 complex exhibits several activities that are not observed in the absence of NBS1, including partial DNA duplex unwinding and ecient cleavage of fully paired hairpins (Paull and Gellert, 1999) . Apart from its role in double-strand break repair, this complex, or individual complex components, may function in other aspects of the DNA damage response. Radio-resistant DNA synthesis (RDS), a hallmark of ataxia telangiectasia (A-T) cells (Painter and Young, 1980) , has also been observed in NBS1-de®cient cells, implying a role for NBS1 in S phase DNA damage checkpoint control, which could represent a potential mechanism for downregulation of DNA synthesis should DNA be damaged during the early stages of S phase (Painter and Young, 1987 ).
BRCA1 appears to interact with the RAD50/ MRE11/NBS1 complex directly through RAD50 . Similar to the formation of the RAD50/MRE11/NBS1 complex, the association of BRCA1 with this complex does not change in response to DNA damage. Rather, the nuclear partitioning of this BRCA1-containing complex changes and BRCA1 forms ionizing irradiation-induced foci (IRIF), which is also a characteristic of RAD50, MRE11 and NBS1 (Maser et al., 1997) . Upon IR treatment, BRCA1 nuclear dots originally observed in untreated cells are disrupted, and later gradually reassemble into bright foci, which also colocalize with RAD50 foci in the portion of cells that display both RAD50 and BRCA1 foci . It has been suggested that RAD50/MRE11 complexes localize to the sites of DSB upon IR (Nelms et al., 1998) ; therefore, the colocalization of BRCA1 with this complex implies that BRCA1 is relocated to the sites of DSB upon IR. This dynamic redistribution of BRCA1 could re¯ect an aspect of the cellular response to DNA damage in a manner analogous to the translocation of RAD50 complexes to the sites of DSBs. Consistently, BRCA1 has been found to be important for ecient formation of IRIF . Its association with the RAD50/ MRE11/NBS1 complex suggests that BRCA1 could participate directly in the RAD50-mediated DNA repair process. Alternatively, BRCA1 could facilitate the repair of DSBs on chromatin templates through its direct recruitment of chromatin remodeling activities ). The precise role that BRCA1 plays in complex with RAD50/MRE11/NBS1, however, remains to be de®nitively established.
Besides RAD50/MRE11/NBS1, other components involved in DNA damage repair, such as MSH2, MSH6, MLH1, ATM and BLM, have been found to reside in a large BRCA1-containing DNA repair complex (Wang et al., 2000) . In addition, DNA replication factor C and PCNA were also found in this complex (Wang et al., 2000) . This complex has been proposed to represent a BRCA1-associated genome surveillance complex (BASC) since many of its constituent proteins individually recognize distinctly abnormal DNA structures, such as double-strand breaks, base-pair mismatches, and stalled replication forks. Many of these proteins are involved in replication or repair of damage that can occur at replication forks. Therefore, the association of BRCA1 with these proteins suggests that BRCA1 may also participate in the resolution of aberrant DNA structures that occur during DNA replication or when DNA replication is stalled (Wang et al., 2000) . Consistent with this notion is the previous observation that BRCA1 foci at S phase disperse in response to DNA damage or replication blocks, and relocalize to PCNAcontaining structures (Scully et al., 1997b) , suggestive of a role for BRCA1 in replicational DNA repair.
BRCA1 has also been proposed to associate, through a region encoded by the 3' end of exon 11, with RAD51 although it is still not clear whether this association is mediated by direct or indirect interaction (Scully et al., 1997c) . This association is supported primarily by the observation that BRCA1 foci partially colocalize with RAD51 foci during S phase, and relocalize to PCNA-containing structures in response to UV-treatment or replication block by hydroxyurea (Scully et al., 1997b) . BRCA1 has also been observed in IR-induced RAD51 foci; however, such foci are distinct from those comprising BRCA1 and the RAD50/MRE11/NBS1 complex . While the RAD50/MRE11/NBS1 complex has been proposed to function in end-processing, an early step in both homologous recombination and non-homologous end-joining based repair of DNA double-strand breaks, RAD51 is involved in strand-exchange, a later step in homologous recombination (reviewed by Baumann and West, 1998) . The biological implications underlying the dual participation of BRCA1 in two distinct steps of homology-based recombinational DSB repair remain to be resolved.
BRCA1 in DNA double-strand break repair Cumulative evidence is consistent with the direct participation of BRCA1 in DNA DSB repair through both homologous recombination and NHEJ. The develop- Figure 3 BRCA1 and BRCA2 participate in DSB repair. BRCA1 forms a complex with RAD50, MRE11, NBS1 and other proteins. This complex is involved in both homologous recombination and non-homologous end-joining processes of DSB repair. BRCA2 forms a complex with RAD51, which is involved in DNA strand exchange during homologous recombination Lessons learned from BRCA1 and BRCA2 L Zheng et al ment of an in vivo DSB repair assay system (Moynahan et al., 1999) in which the frequency of repair at a de®ned DSB may be measured has proven instrumental in elucidating the contribution of BRCA1 to both homologous and nonhomologous recombinational repair pathways (Figure 3 ). Using this system, Brca1-de®cient embryonic stem cells were found to exhibit a signi®cant defect in homologous recombination (Moynahan et al., 1999) . A recent study using a similar approach has shown that NHEJ is also severely reduced in Brca1-de®cient mouse embryonic ®broblast cells (Zhong et al., submitted) although such a defect was not observed previously in embryonic stem cells (Moynahan et al., 1999) . Moreover, retroviral integration, which relies on the NHEJ-dependent repair pathway, is inecient in Brca1-de®cient embryonic ®broblast cells (Zhong et al., submitted) . This same study also demonstrated that Brca1-de®cient cell extract as well as normal cell extract blocked by BRCA1-speci®c antibodies both exhibit reduced activity in catalyzing DNA end-joining in vitro, suggesting that BRCA1 participates directly in the NHEJ repair process (Zhong et al., submitted) . The involvement of BRCA1 is both homologous recombination and NHEJ is consistent with its interaction with the RAD50/MRE11/NBS1 complex, which is required for both DNA recombination processes. It has been demonstrated that cells with component defects in either of these recombinational repair pathways are prone to radiation hypersensitivity, genetic instability, and increased tumor susceptibility (Di®lippantonio et al., 2000; Gao et al., 2000; Varon et al., 1998a) .
It is worth noting that both BRCA1 and BRCA2 genes are not evolutionarily conserved, while the basic DSB repair machinery itself is (reviewed by Featherstone and Jackson, 1999; Karran, 2000) . BRCA1 is therefore dispensable for normal frequencies of DNA recombination and DSB repair in lower eukaryotes such as Saccharomyces Cerevisiae. Thus, BRCA1 is likely to increase the repair eciency of damaged DNA in the context of a much larger and more complicated chromatin environment such as that of the mammalian genome. Moreover, BRCA1 could additionally function to eect the ecient coordination of DNA repair with other cellular processes that are critical to support metazoan existence.
BRCA1 in transcription-coupled repair Brca1-de®cient mouse embryonic stem cells have been shown to be defective in the ability to carry out transcriptioncoupled repair (TCR), a process in which DNA damage is repaired more rapidly in transcriptionally active DNA than in the genome as a whole (Gowen et al., 1998) . DNA damage induced by UV as well as oxidative DNA damage caused by IR or H 2 O 2 can be repaired by TCR. It has been demonstrated that Brca1-de®cient cells are defective in TCR of oxidative DNA damage, but not in TCR of UV-induced DNA damage. Consistent with this observation, these Brca1-de®cient cells are hypersensitive to oxidative DNA damage. Presently, it is not clear whether BRCA1 itself participates directly in TCR or, alternatively, whether it functions as a transcription factor essential for the expression of genes whose products are required for TCR of oxidative damage (Gowen et al., 1998) .
The hypersensitivity of BRCA1-de®cient cells to IR and H 2 O 2 cannot be explained exclusively by a defect in TCR because DSB are also generated following treatments with these two agents. This observation is consistent with the aforementioned role of BRCA1 in recombinational repair of DSBs through both homologous and nonhomologous pathways. Therefore, BRCA1 is involved in multiple DNA repair pathways that ensure global genome stability.
BRCA1 in DNA-damage checkpoint controls DNA repair process must be coordinated with cell cycle control mechanism to ensure that damaged chromosomal DNA is ®xed before it is replicated or segregated. BRCA1 appears to play such a role through its dual participation in the repair process of damaged DNA and in cell cycle checkpoint control. Although the underlying mechanism for BRCA1 functioning in checkpoint control has not been clari®ed, the observations showing the eects of BRCA1 on the transcription of genes involved in cell cycle controls, as aforementioned, may evoke a model for it. Alternatively, BRCA1 may regulate DNA damage-induced checkpoint through its associated DSB repair complexes. Recently, a potential role of Rad50/Mre11 in G2/M checkpoint was suggested by showing that rad50 or mre11 mutants can suppress the adaptation of hdf1, a yeast Ku70 mutant, to G2/M arrest after DNA damage . Whether the interaction between BRCA1 and the RAD50/MRE11/NBS1 complex is involved in G2/M checkpoint control remains to be examined.
BRCA1 in DNA-damage signaling An important step in the cellular response to DNA damage is to transduce damaged signals to downstream eectors involved in the arrest of cell cycle and repair of damaged DNA. Many kinases have been implicated in the transduction of DNA damage signals. In mammalian cells, several kinases, such as ATM, ATR, DNA-PK, Chk1 and hCds1/Chk2 are activated in response to DNA damage (for review see Dasika et al., 1999; and references therein) . Consistently, ATM-de®cient cells are defective in DNA damage-induced checkpoint control as well as DNA repair (reviewed by Shiloh, 1997) . Chk2, which itself is phosphorylated and regulated by ATM, is essential for G2/M checkpoint control (Matsuoka et al., 1998) .
BRCA1 becomes hyperphosphorylated in response to treatment of cells with a variety of DNA damaging agents, including UV, hydroxyurea, mitomycin C, MMS, IR, H 2 O 2 and adriamycin (Chen et al., 1996c; Li et al., 1999b; Scully et al., 1997b) . Recently, multiple phosphorylation sites at serine (S) residues, including S1330, S1423, S1466, S1524 and S1542, have been detected by mass spectrometry analysis of recombinant BRCA1 peptides phosphorylated in vitro by ATM (Cortez et al., 1999) . Moreover, S1387 was shown to be phosphorylated by ATM in vitro based on a screening of peptides containing potential ATM-phosphorylation sites (Lim et al., 2000) . Among these serine residues, S1457, S1524 and S1542 were shown to be phosphorylated in vivo by mass spectrometry analysis of transfected BRCA1 in irradiated human 293T cells (Cortez et al., 1999) . Furthermore, the phosphorylation-defective mutant of BRCA1 carrying changes of both serines at residues 1423 and 1524 to alanines failed to rescue radiation hypersensitivity in BRCA1-de®cient cells (Cortez et al., 1999) . These data suggested that ATM-dependent phosphorylation of BRCA1 on S1423 and S1524 is necessary for BRCA1-mediated DNA damage response.
However, as detected by its mobility shift in SDS gels, hyperphosphorylated forms of BRCA1 still exist in ATM-de®cient cells upon DNA damage (Scully et al., 1997c) , suggesting that multiple kinase activities are responsible for DNA damage-induced hyperphosphorylation of BRCA1. Consistently, hCds1/ChK2 has been shown to phosphorylate BRCA1 on serine 988 upon IR . The BRCA1 mutant carrying the S988A mutation also fails to rescue radiation hypersensitivity of BRCA1-de®cient HCC1937 cells. It is therefore possible that ATMdependent and Chk2-dependent phosphorylation of BRCA1 are involved in cellular responses to dierent levels of DNA damage. Alternatively, two kinase pathways may, through modulating dierent functions of BRCA1, regulate multiple downstream eectors.
In addition to ATM and hCds1/Chk2, ATR and DNA-PK were shown to phosphorylate BRCA1 in vitro (Lim et al., 2000) . It remains to be determined whether these kinases are involved in phosphorylation of BRCA1 in vivo. Moreover, additional kinases responsible for phosphorylation of BRCA1 upon treatment of cells with other DNA damaging agents such as UV and MMS remains to be identi®ed.
Functional links of ATM and BRCA1 in DNA damage signaling Phosphorylation of BRCA1 is apparently important for a proper DNA damage response. However, it remains unclear how phosphorylation modulates the activities of BRCA1. Since BRCA1 forms IRIF that colocalize with RAD50/MRE11/ NBS1 and DNA-damage sites following IR-treatment, it is obvious to speculate that phosphorylation of BRCA1 is involved in this process. Mutation of ATM or hCds1/Chk2 phosphorylation sites on BRCA1, however, did not aect BRCA1 foci formation in response to IR (Cortez et al., 1999; Lee et al., 2000) . Therefore, it is likely that ATM or Chk2-mediated phosphorylation of BRCA1 regulates the activities of BRCA1 in DNA repair processes, rather than targeting the BRCA1-RAD50 complexes to damaged sites. Alternatively, phosphorylation of BRCA1 may in¯uence the activities of BRCA1 in transcription regulation of DNA damage responsive genes.
Nevertheless, the kinase activity of ATM has been functionally linked to BRCA1 through the BRCA1-associated protein, CtIP. Recent studies indicated that ATM phosphorylates CtIP in vitro and in vivo following IR-treatment . This ATMdependent phosphorylation of CtIP is required for dissociation of the CtIP/CtBP corepressor complex from BRCA1 and, subsequently relieving BRCA1-mediated repression of GADD45 transcription ( Figure  4) . Therefore, ATM can modulate the activities of BRCA1, not only through a direct modi®cation on BRCA1, but also through phosphorylation of its binding partner, CtIP. These studies suggest that CtIP mediates one of the functional links between ATM and BRCA1 in DNA-damage signaling pathways.
An integrated signaling network in BRCA1-mediated DNA-damage response BRCA1 and CtIP are apparently not the only proteins that are phosphorylated by ATM upon IR-treatment. It has been demonstrated that ATM phosphorylates multiple components in BRCA1-containing complexes, including p53 and NBS1. ATM-dependent phosphorylation of p53 is required for G1/S checkpoint and p53-mediated apoptosis (Canman et al., 1998) . Phosphorylation of NBS1 by ATM is necessary for the formation of IRIF, suggesting that one function of NBS1 activated by ATM is to relocalize Rad50/Mre11/NBS1 to sites of DNA damage (Zhao et al., 2000) . Derivatives of NBS1 carrying mutations in the ATM-phosphorylation sites fail to correct the RDS defect in NBS1-de®cient cells, suggesting that another function of NBS1 activated by ATM is in S phase checkpoint control (Gatei et al., 2000; Lim et al., 2000; Wu et al., 2000; Zhao et al., 2000) . These BRCA1-associated proteins are also likely to be regulated by other kinases such as ATR and Chk2. Interestingly, MRE11 is also phosphorylated upon DNA damage in an NBS1-dependent manner, although the consequences of this phosphorylation event remains unknown (Dong et al., 1999) . It is apparent that a complicated but integrated network is utilized to transmit DNA-damage signals to BRCA1 and its associated proteins, and regulate their functions at dierent levels. Figure 4 BRCA1 is involved in cellular response to DNA damage. BRCA1 participates in DNA damage repair and cell cycle checkpoint control, and coordinates both cellular processes in response to DNA damage. BRCA1 may directly participate in the DSB repair process through interacting with the RAD50/ MRE11/NBS1 complex. BRCA1 may control cell cycle checkpoint by induction of p21 or GADD45 transcription. Upon IR, CtIP is phosphorylated by ATM. Phosphorylated CtIP dissociates from BRCA1, leading to the relief of repression activity of BRCA1 and, thereby, the induction of GADD45 or p21. Induction of p21 or GADD45 results in cell cycle arrest at G1/ S or G2/M transition. The BRCA1/RAD50/MRE11/NBS1 complex may be also involved in the cell cycle checkpoint control Lessons learned from BRCA1 and BRCA2 L Zheng et al
Other potential functions of BRCA1
BRCA1 also associates with BARD1 (Wu et al., 1996) , which functionally interacts with polyadenylation factor CstE-50 (Kleiman and Manley, 1999) , and with BAP1 (Jensen et al., 1998) , which is a de-ubiquitinating enzyme, suggesting two additional roles of BRCA1 in RNA polyadenylation and in ubiquitin-dependent protein degradation. The potential role of BRCA1 in post-transcriptional RNA processing may coordinate with its role in transcriptional regulation. The Nterminal RING domain of BRCA1 has been suggested to function with or as a ubiquitin ± protein ligase (Lorick et al., 1999) , which is particularly interesting as protein degradation may in¯uence the processes of transcription and DNA repair. In sum, it remains to be elucidated how BRCA1 participates in these pathways and the biological signi®cance of these functions.
BRCA2 in transcriptional regulation
Contrary to BRCA1, the role of BRCA2 in transcriptional regulation is less certain. However, several lines of evidence support such a role for BRCA2. First, the product of BRCA2 exon 3 (amino acids 23 ± 105), when fused to DNA-binding domains, activates transcription in yeast and mammalian cells (Milner et al., 1997) . Consistently, the amino acid sequence of BRCA2 within this region shares some similarity with the transactivation domain present in c-Jun (Milner et al., 1997) . Intriguingly, in a breast cancer case of a Swedish patient, a deletion of exon 3 at the BRCA2 allele was found (Nordling et al., 1998) . Moreover, a missense mutation (tyrosine 42 to cysteine), identi®ed in a familial breast cancer case, within the primary activating region severely compromised the transactivation activity of BRCA2 (Milner et al., 1997) suggesting that the abrogation of the BRCA2 putative transcription activity may be a predisposition to tumor development. Second, overexpression of exogenous BRCA2 inhibited p53-mediated transcription (Marmorstein et al., 1998) . Third, BRCA2 was demonstrated to have histone acetyltransferase activity and consistently, it was found to interact with the transcription co-activator P/CAF (p300/CBP-associated factors), suggesting a role of BRCA2 as a coactivator (Fuks et al., 1998) . To date, it remains unclear what the exact role of BRCA2 is in the regulation of transcription. More importantly, it will be critical to understand how the loss of this putative transcriptional activity of BRCA2 contributes to tumorigenesis.
BRCA2 in DNA repair
The interaction between BRCA2 and RAD51 The potential role of BRCA2 in DNA repair was ®rst revealed by identi®cation of its interaction with human or mouse RAD51 in yeast two-hybrid screens (Chen et al., 1998b; Sharan et al., 1997; Wong et al., 1997) . Consistently, mouse embryos lacking BRCA2 exhibit similar radiation hypersensitivity to mouse embryos lacking RAD51 (Sharan et al., 1997) . Human and mouse RAD51 are mammalian homologs of the Escherichia coli protein RecA (Clark, 1996) and of yeast ScRad51 (Shinohara et al., 1992) , a member of the RAD52 epistasis group in Saccharonmyces cerevisiae (McKee and Lawrence, 1980) . All of the proteins in the RAD52 epistasis group are required for the repair of DSB and for mitotic and meiotic recombination in yeast. Eukaryotic RAD51 protein, similar to RecA, has ATP-dependent DNA binding activity and multimerizes to form a nucleoprotein ®lament on single-stranded DNA. Furthermore, RAD51 can catalyze homologous DNA pairing and DNA strand exchange in an in vitro recombination reaction (Baumann et al., 1996; Baumann and West, 1997; Sung, 1994; Sung and Robberson, 1995) . Apparently, multiple discrete regions in BRCA2, including six BRC repeats, mediate its interaction with RAD51 (Chen et al., 1998b; Sharan et al., 1997; Wong et al., 1997) . It is, therefore, tempting to hypothesize that BRCA2 may increase the eciency for RAD51-nucleoprotein ®lament formation by binding multiple RAD51 subunits. It would be interesting to determine the precise stoichiometry of the BRCA2-RAD51 complex, and examine how BRCA2 in¯uences homologous DNA paring and strand exchange activity of mammalian RAD51. It has been shown that other protein components, such as a single-strand DNA binding protein, replication protein A, RAD52, and RAD55/RAD57 heterodimer are necessary for the formation of the RAD51-®lament by enhancing the activity of RAD51 (reviewed by Shinohara and Ogawa, 1999) . It is conceivable that BRCA2 is also required for the formation of the RAD51-®lament and the proper function of RAD51 (Figure 3) . Consistent with this notion, IR-induced RAD51 foci formation is diminished in BRCA2-de®cient cells (Yu et al., 2000; Yuan et al., 1999) or in cells in which the interaction between BRCA2 and RAD51 is speci®cally disrupted (Chen et al., 1998a) . Therefore, BRCA2 appears to be necessary for the assembly of RAD51 complexes upon DNA damage.
Interaction between BRCA1 and BRCA2 It has been suggested that BRCA1 and BRCA2 interact in vivo (Chen et al., 1998a) . A region adjacent to, but not at the extreme C-terminus of BRCA1 was shown to mediate this interaction. BRCA2 also localizes in nuclear dots in mitotic cells at S or G2 phase and, colocalizes with BRCA1 on synaptonemal complexes of meiotic chromosomes (Chen et al., 1998a) . As discussed before, BRCA1 colocalizes with RAD51 in a speci®c period after DNA damage, and this association is distinct from the colocalization of IR-induced BRCA1/RAD50 foci. In short, the functional consequence of the interaction between BRCA1 and BRCA2 remains elusive, although it is possible that this interaction may be involved in coupling the functions of RAD50 and RAD51.
BRCA2 in DSB repair By revealing the interaction between BRCA2 and RAD51, the potential role of BRCA2 in DSB repair through homologous recombination is supported, but direct evidence is still desired. Brca2-truncated mouse lymphocytes are hypersensitive to mitomycin C (MMC) (Yu et al., 2000) , which causes DNA interstrand cross-links that are repaired primarily by recombination between homologous sequences . Other mutant cells lacking DNA recombination genes such as XRCC2 and XRCC3 are also hypersensitive to MMC (Liu et al., 1998) . Moreover, gross chromosomal rearrangements and genetic exchange between nonhomologous chromsomes that are observed in BRCA2-de®cient cells are proposed to result from a defect in homologous recombination. Taken together, these observations present further evidence for a role of BRCA2 in homologous recombination. Like BRCA1, BRCA2 is not evolutionarily conserved, implying that BRCA2 is not essential for the basic machinery of DSB repair, but is necessary for ecient DNA repair required by higher organisms to ensure the integrity of a more complicated genome.
BRCA2 in DNA-damage induced checkpoint control Although the enforcement of checkpoints activated by DNA damage is largely preserved in cells from mice homozygous for Brca2 truncations , tumors formed by these mice display loss of the mitotic spindle checkpoint, presumably due to acquired mutations in BUB1, MAD3L and p53, three genes involved in mitotic checkpoint control . It is possible that Brca2 truncation at exon 11, retaining the ®rst three BRC repeats, possesses a partial function that is able to rescue the embryonic lethality and preserve an intact DNA damage-induced checkpoint (Chen et al., 1998a) . The speci®c disruption of the interaction between RAD51 and BRCA2 by expressing a peptide containing BRC repeats results in loss of G2/M checkpoint control, thereby, suggesting that the role of BRCA2 in G2/M checkpoint may be associated with its function in DNA repair (Chen et al., 1998a) .
Perspectives
Both BRCA1 and BRCA2 have been proposed to be caretakers that function in the maintenance of global genome stability. Although functional inactivation of a caretaker is not sucient to convert a normal cell to a cancer cell, it destabilizes the genome such that mutations in other genes can accumulate more frequently . The subsequent mutational inactivation or deletion of a gatekeeper gene represents the precipitating event that initiates transformation to the neoplastic state. Gatekeepers are exempli®ed by genes that encode activities that directly regulate cell growth, and loss of gatekeeper activity leads to aberrant control of cell growth or cell death. While this hypothesis has provided a framework for understanding the contribution of inactivation of tumor suppressor genes to the genesis of cancer, its arbitrary distinction between caretakers and gatekeepers may obscure what in actuality represents the contribution of a potentially overlapping set of functional activities. More speci®cally, it seems evident that classicallyde®ned gatekeepers could reasonably function as caretakers and vice versa. The cases of BRCA1 BRCA2, and p53 provide examples to illustrate this point.
In a variety of model systems, functional inactivation of BRCA1/2 leads to overt global genome instability; BRCA1/2 therefore clearly conform to the class of caretakers. However, while p53 ful®ls the de®nition of a gatekeeper in many instances, other models exist in which it functions more akin to a caretaker. For example, while p53 is likely to play a role in restraining breast cancer formation in BRCA1/2 mutation carriers, the loss of its function does not appear to represent the threshold event that is proposed to accelerate the rate of mutation in cancer development. Rather, in these instances, functional loss of p53 appears only to permit cells with accumulated genetic abnormalities by bypass of checkpoint control and DNA-damage induced apoptosis. A similar eect is observed in a Ku80 de®cient mouse tumor model. In this system, the absence of Ku80 precipitates genomic instability, which is not augmented by the additional loss of p53 (Di®lippantonio et al., 2000) . Under such circumstances, it appears that inactivation of BRCA1/2 (or Ku80) and inactivation of p53 represent two distinct but coordinate events; the ®rst destabilizes the genome, while the second assists the ®rst in evading the custodial eects of cellular surveillance systems such as DNA-damage induced checkpoint control or apoptosis. BRCA1/2 and p53 thus appear to function as a coordinate caretaker; inactivation of both genes will permit cells with unstable genomes to proliferate freely and ultimately become tumorigenic.
Consistent with the possibility that p53 may function as a caretaker, germline inactivation of p53 itself will lead to genome instability and an increased frequency in tumor formation (reviewed by Lane, 1992) . Hence, p53 appears to conform to the class of caretakers which are proposed to function as guardians of the genome (Lane, 1992) . Genome instability need not necessarily arise through germline inactivation of speci®c genes such as BRCA1 and BRCA2 that function in the maintenance of chromosomal integrity, but conceivably could arise by spontaneous insult from intrinsic or extrinsic agents. For example, environment, age, diet, or other etiological factors could represent causative agents in the precipitation of chromosomal damage in sporadic cancers, as could sporadic mutations in genes involved in the maintenance of chromosomal integrity. As it represents the most direct means to eect bypass of cellular surveillance systems, p53 mutation is most frequently observed in breast cancers or in familial cancers with BRCA1/2 mutations. However, mutational inactivation of genes that function in p53-mediated pathways, such as p19ARF (de Stanchina et al., 1998; Pomerantz et al., 1998; Zindy et al., 1998) , or genes that function in other checkpoint control pathways, such BUB1, have also documented in human cancers (Cahill et al., 1998) .
Thus while p53 can evidently ful®ll, at least in part, the duties of a caretaker, it must be emphasized that it can also function as a classical gatekeeper. Its dual character likely derives from the fact that p53 exerts its in¯uence over cellular functions other than DNAdamage induced checkpoint conrol and apoptosis. As a sequence-speci®c transcription factor, p53 regulates multiple genes involved in many cellular pathways Prives and Hall, 1999; Tokino and Nakamura, 2000) . Inactivation of p53 could lead to uncontrolled proliferation and/or invasive growth and, in so doing, contribute to a distinct step in malignant transformation. By similar reasoning, it seems plausible that BRCA1/2, which clearly function as caretakers in the sense that their inactivation is invariably accompanied by widespread genome instability, could also ful®ll the role of gatekeepers. Indeed, inactivation of BRCA1/2 apparently accelerates the rate of mutation and increases the incidence of tumor formation, since predisposed individuals who inherit one mutant copy of BRCA1 or BRCA2 experience a 10-fold greater chance of developing breast cancer than non-predisposed individuals (Hall et al., 1990; Wooster et al., 1994) . BRCA1/2 function in sequence-speci®c transcriptional regulation, and it has been demonstrated that BRCA1 can regulate a diverse array of genes involved in cell proliferation, cell cycle control and dierentiation. Moreover, BRCA1/2 are unique to metazoans, a fact that distinguishes them from other member genes in the caretaker class. These distinctive features of BRCA1/2 render it possible that their functional inactivation may, apart from their participation in the maintenance of global genome stability, contribute to a critical step in malignant transformation during breast tumorigenesis. Accordingly, it will be important to examine whether reintroduction of BRCA1/2 at levels approaching those occurring physiologically can rescue a transformed cellular phenotype.
In sporadic breast cancers and other cancers, p53 mutations must arise through selection during clonal evolution. This implies that p53 gene mutations are more frequently selected because they either confer growth advantages to tumor cells or, alternatively, that the p53 gene locus is more susceptible to mutation. On the other hand, the fact that somatic mutations in BRCA1/2 are rare events may imply that no growth advantage accompanies the loss of BRCA1/2 function in the adult breast tumor cells, and perhaps even normal adult mammary gland cells. This has raised speculation that BRCA1/2 have distinct functions at dierent stages of mammary gland development. Consistent with this notion is the observation that expression of BRCA1 and BRCA2 is regulated during this process (Lane et al., 1995; Marquis et al., 1995; Rajan et al., 1996) . In this regard, understanding how BRCA1/2 contribute to mammary gland development might weigh equally as important as understanding how their mutational inactivation leads to breast cancer formation.
The rarity of BRCA1/2 gene mutations in sporadic breast and ovarian cancer cases implies that aberrant expression of the BRCA1/2 genes or, alternatively, improperly regulated activity of their encoded products could contribute to non-familial breast cancer formation. Consequently, detailed knowledge of their normal biological function and regulation will be required for a thorough appreciation of how direct or indirect functional inactivation of BRCA1/2 ultimately leads to breast tumorigenesis. Speci®cally, functional analyses of BRCA1/2-associated proteins and the operative mechanisms underlying their respective roles in transcription regulation and DNA damage repair could contribute to a more complete understanding of the etiological bases of the remaining 90% of breast cancer cases that do not involve germline BRCA1/2 mutations.
Another unsolved question concerns the tissuespeci®c nature of tumor suppressive properties of BRCA1/2. BRCA1/2 are expressed ubiquitously and participate in universal cellular pathways; however, functional inactivation of BRCA1/2 leads speci®cally to breast or ovarian cancer formation. One possibility to account for this apparent paradox is that BRCA1/2, apart from their universal activities, exert distinct functions in breast or ovarian tissues. For example, BRCA1/2 may transcriptionally regulate speci®c genes that are critical for growth control of mammary gland cells. Consequently, a more complete understanding of how BRCA1/2 target speci®c genes for transcriptional regulation may illuminate unique pathways leading to breast tumorigenesis. Furthermore, the fact that BRCA1 has been implicated in the modulation of estrogen signaling suggests a potential mechanism through which its functional inactivation may impact cells in a speci®c hormonal environment. It remains to be established whether and how BRCA1 modulates the estrogen response in vivo and how its loss aects this cellular response.
An alternative possibility to account for the breastand ovarian-speci®c nature of BRCA1/2 tumor suppression is that the activities of BRCA1/2 are more important for tumor suppression in these as opposed to other tissues. BRCA1/2 function ubiquitously in the maintenance of genomic integrity, and it is probable that the DNA damage-induced cellular signaling pathways that converge on them are conserved in most cell types. Indeed, the DNA damage-induced target genes controlled transcriptionally by BRCA1, as well as the components of the DNA double-strand break repair machinery with which it functionally interacts exhibit broad cell type expression pro®les. It thus appears likely that BRCA1 occupy a fundamental and universally conserved role in the DNA damage response through their control of transcription and DNA repair. The tissue-speci®city of their tumor suppressive properties may therefore lie not within the tissue-speci®c regulation of BRCA1/2 activity but, rather, in the tissue-speci®c nature of the DNA damage to which it responds. In this regard, it is signi®cant that speci®c metabolic byproducts of estrogen itself have been documented to be genotoxic in nature (reviewed by Liehr, 2000) . These collective observations raise the intriguing possibility that BRCA1/2 may play a role in protecting breast and ovarian tissue from estrogeninduced DNA damage. Clearly, a precise understanding of the molecular basis underlying the tissuespeci®city of the tumor suppressive properties of BRCA1/2 will be essential for the design and implementation of strategies to delay, and ultimately to prevent, breast tumor formation.
Recent advances in the studies of BRCA1/2 have also provided insight into the mechanistic role of DSB repair in the suppression of tumorigenic mutations. It is well-established that cancer-causing mutations such as large deletion mutations, chromosomal translocations, and partial or complete chromosome loss often arise from gross chromosomal rearrangement and lead to loss of heterozygosity which is implicated in the inactivation of tumor suppressor genes (Lasko et al., 1991) . Hence, it has been proposed that one role for BRCA1/2 in homologous recombination-based DSB repair is to suppress gross chromosomal rearrangements (GCR) including genetic exchange between nonhomologous chromosomes after chromosome breakage (Moynahan et al., 1999; Yu et al., 2000) . However, it is not presently clear whether GCR that are observed in BRCA1/2 mutant cells represent resolution of chromosome breaks by non-homology-based repair pathways including NHEJ as an errorprone compensation for defective homologous recombination-based mechanisms. On the contrary, it has recently been demonstrated that inactivation of individual NHEJ DNA repair pathway components, such as XRCC4 and Ku, also leads to severe GCR (Di®lippantonio et al., 2000; Gao et al., 2000) . Moreover, a severe defect in NHEJ has recently been observed in Brca1-de®cient MEF cells (Zhong et al., submitted) . Thus, both homologous recombination and NHEJ are likely to be required for maintaining genome integrity in the face of chromosome breakage. Defects in either of these repair pathways could result in inecient and improper repair of damaged chromosomes. These latter studies therefore imply that gross chromosomal rearrangements may not be a consequence of non-homology-dependent DNA repair which is proposed to be error-prone, but due instead to an unknown mechanism that remains to be de®ned.
Clearly, a more precise understanding of BRCA1/2 function at the mechanistic level will not only provide insight into the pathogenesis of breast cancer, but also enhance our knowledge of the molecular basis by which a cell maintains its genomic integrity. We can also expect that novel therapeutic tools designed to speci®cally interfere with these molecular events will be developed and tested for tumor suppression in a growing company of genetically de®ned mammary tumor models.
